Utility of antiphosphorylated H2AX antibody (γ-H2AX) in diagnosing metastatic renal cell carcinoma

Applied Immunohistochemistry and Molecular Morphology

Volumn 16, Issue 4, 2008, Pages 349-356

  Wasco, Matthew J ^a   Pu, Robert T ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

H2AX; Differential diagnosis; Metastatic RCC; RCC Ma

Indexed keywords

HISTONE H2AX; DIAGNOSTIC AGENT; H2AFX PROTEIN, HUMAN; HISTONE; MONOCLONAL ANTIBODY;

ADRENAL CORTEX CARCINOMA; ADULT; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SENSITIVITY AND SPECIFICITY; TISSUE MICROARRAY; COMPARATIVE STUDY; IMMUNOLOGY; KIDNEY TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PHOSPHORYLATION;

ANTIBODIES, MONOCLONAL; CARCINOMA, RENAL CELL; FEMALE; HISTONES; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PHOSPHORYLATION;

EID: 48949083652     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e3181577993     Document Type: Article

References (18)

1. Ghorab Z, Jorda M, Ganjei P, et al. Melan a (a103) is expressed in adrenocortical neoplasms but not in renal cell and hepatocellular carcinomas. Appl Immunohistochem Mol Morphol. 2003;11:330-333.
2. McGregor DK, Khurana KK, Cao C, et al. Diagnosing primary and metastatic renal cell carcinoma. Am J Surg Pathol. 2001;25: 1485-1492.
3. Simsir A, Chhieng D, Wei XJ, et al. Utility of CD10 and RCCma in the diagnosis of metastatic conventional renal-cell adenocarcinoma by fine-needle aspiration biopsy. Diagn Cytopathol. 2005;33:3-7.
4. Zimmerman RL, Burke MA, Young NA, et al. Diagnostic value of hepatocyte paraffin 1 antibody to discriminate hepatocellular carcinoma from metastatic carcinoma in fine-needle aspiration biopsies of the liver. Cancer. 2001;93:288-291.
5. Fetsch PA, Powers CN, Zakowski MF, et al. Anti-alpha-inhibin: marker of choice for the consistent distinction between adrenocortical carcinoma and renal cell carcinoma in fine-needle aspiration. Cancer. 1999;87:168-172.
6. Renshaw AA, Granter SR. A comparison of A103 and inhibin reactivity in adrenal cortical tumors: distinction from hepatocellular carcinoma and renal tumors. Mod Pathol. 1998;11:1160-1164.
7. Yoshida SM, Imam A. Monoclonal antibody to a proximal nephrogenic renal antigen: immunohistochemical analysis of formalin fixed, paraffin-embedded human renal cell carcinomas. Cancer Res. 1989;49:1802-1809.
8. Avery AK, Beckstead J, Renshaw AA, et al. Use of antibodies to RCC and CD10 in the differential diagnosis of renal neoplasms. Am J Surg Pathol. 2000;24:203-210.
9. Gokden N, Mukunyadzi P, James JD, et al. Diagnostic utility of renal cell carcinoma marker in cytopathology. Appl Immunohistochem Mol Morphol. 2003;11:116-119.
10. Abrahams NA, MacLennan GT, Khoury JD, et al. Chromophobe renal cell carcinoma: a comparative study of histological, immunohistochemical and ultrastructural features using high throughput tissue microarray. Histopathology. 2004;45:593-602.
11. Bartkova J, Horejsi Z, Koed K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 2005;434:864-870.
12. Grignon DJ, Eble JN, Bonsib SM, et al. Tumors of the Kidney. In: Eble JN, Sauter G, Epstein JI, et al, eds. Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press; 2004:23-25.
13. Pan CC, Chen PC, Tsay SH, et al. Differential immunoprofiles of hepatocellular carcinoma, renal cell carcinoma, and adrenocortical carcinoma: a systemic immunohistochemical survey using tissue array technique. Appl Immunohistochem Mol Morphol. 2005;13: 347-352.
14. Yang B, Guo M, Herman JG, et al. aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am J Pathol. 2003;163:1101-1107.
15. Morris MR, Hesson LB, Wagner KJ, et al. Multigene methylation analysis of Wilms' tumour and adult renal cell carcinoma. Oncogene. 2003;22:6794-6801.
16. Bartkova J, Bakkenist CJ, Rajpert-De Meyts E, et al. ATM activation in normal human tissues and testicular cancer. Cell Cycle. 2005;4:838-845.
17. Munshi A, Kurland JF, Nishikawa T, et al. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin Cancer Res. 2005;11:4912-4922.
18. Munshi A, Tanaka T, Hobbs ML, et al. Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Mol Cancer Ther. 2006;5:1967-1974.